Blood cancers make up more than 100 different diagnoses in the current classification system. And there are three main groups of blood cancer: leukemia, lymphoma, and myeloma. One of the most common leukemias in adults is chronic lymphocytic leukemia (CLL). In this episode of Real World Talk, our host Ming He welcomes Paul Barr, MD, the medical director of the Clinical Trials Office of the Wilmot Cancer Institute. They talk about the importance of Blood Cancer Awareness Month, the development of CLL treatments, and the potential use of real-world data in blood cancer research.

The healthcare ecosystem generates approximately a third of all the new data in the world. And it holds untapped potential for developing new therapies and giving people the opportunity to live longer and healthier. But these data sets are raw and need to be meticulously tabulated into meaningful, targeted information.

Real world data and real-world evidence are powerful tools for scientific researchers, and they have an enormous potential to transform the healthcare space, especially oncology. But, we need to educate the entire ecosystem on the importance of real-world data to be able to reap its full benefits. In this episode of the Real World Talk podcast, we introduce our new CEO – Miruna Sasu. She talks about her plans for COTA, the role of real-world data in clinical trials and drug development, and much more.

In this episode of Real World Talk we welcome Su Huang, the Head of Data Strategy at Datavant. Su shares real-world experiences implementing enterprise data strategies and the efficiencies that can be gained when teams across an organization are involved in the process.

Unlike the controlled settings under which clinical trials are conducted, real-world data is collected from a variety of settings. The FDA recently released draft guidance on how to use real-world data for regulatory submissions. Our team of clinical experts discuss this guidance and its effect on how we generate and apply RWD in clinical development.

Almost 10% of the world’s population suffers from a type of blood cancer. And despite popular opinion, there are actually hundreds of different types of blood cancer, not just leukemia and lymphoma. But are we doing everything in our power when developing clinical trials to improve cancer treatment? Could we include diversity and make trials more accessible to everyone? Our guest today thinks we have more work to do in the blood cancer space. In this episode of the Real World Talk podcast, our host Miruna Sasu welcomes Dr.Gwen Nichols, Executive Vice President and Chief Medical Officer of The Leukemia & Lymphoma Society (LLS). We discuss the importance of making clinical trials more diverse and feasible for patients. We also get into Dr. Gwen’s predictions for the future and why she thinks there’s hope for earlier cancer detection and prevention.